SCHEMBL15845779

SCHEMBL15845779

COc1c(NC(=O)C(C)(C)C)cc(F)c(-c2ccccc2)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CETP P11597 1/20 0.43
ABCB1 P08183 2/20 0.42
ADORA1 P30542 2/20 0.42
KDM4E B2RXH2 6/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PDK1 Q15118 2/20 0.40
PDK2 Q15119 2/20 0.40
PDK3 Q15120 2/20 0.40
PDK4 Q16654 2/20 0.40
TACR1 P25103 1/20 0.40
ALOX12 P18054 2/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 1/20 0.39
TOP2A P11388 1/20 0.38
ACLY P53396 1/20 0.38
POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15845739 0.78 KDM4E (0.40) CETPABCB1KDM4ERAB9ANPC1
SCHEMBL15845699 0.77 MEN1 (0.38) ADORA1KDM4ERAB9ANPC1NPSR1
SCHEMBL15845885 0.77 CYP2C9 (0.44) ADORA1KDM4ERAB9ANPC1NPSR1
SCHEMBL18888424 0.76 GAA (0.41) ABCB1ADORA1ALOX12HSD17B10MEN1
SCHEMBL15845612 0.73 KDM4E (0.42) CETPABCB1KDM4ERAB9ANPC1
SCHEMBL3294448 0.72 ALDH1A1 (0.40) ADORA1KDM4ERAB9ANPC1NPSR1
SCHEMBL9474380 0.70 KDM4E (0.51) ABCB1ADORA1KDM4ENPSR1LMNA
SCHEMBL3296562 0.70 ALDH1A1 (0.40) ADORA1KDM4ERAB9ANPC1NPSR1
SCHEMBL28451945 0.69 PDE4B (0.43) ABCB1KDM4EALDH1A1ACLYMAPT
SCHEMBL8471964 0.69 ALDH1A1 (0.52) ADORA1KDM4ENPSR1TACR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 CETP 2853/4885ABCB1 211/4885ADORA1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.